Source: Health Products Regulatory Authority (ZA) Publisher: Abex Pharmaceutica (Pty) Ltd, Suite C, Rubenstein Ridge, 617 Rubenstein Drive, Moreleta Park, 0181
RISPIDE 1 mg/ml oral solution.
| Pharmaceutical Form |
|---|
|
Oral solution. The solution is clear and colourless. |
1 ml oral solution contains 1 mg of risperidone.
Excipient(s) with known effect: 1 ml oral solution contains 1,5 mg benzoic acid (E210) as preservative
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Risperidone is a selective monoaminergic antagonist with unique properties. Although risperidone is a potent D2 antagonist, which is considered to improve the positive symptoms of schizophrenia, it causes less depression of motor activity and induction of catalepsy than classical antipsychotics. |
| List of Excipients |
|---|
|
Tartaric acid (E334) |
Type III amber glass bottle with a plastic (polypropylene/LDPE) child resistant and tamper-evident cap. RISPIDE oral solution is presented in bottle sizes of 30 ml, 60 ml, 100 ml and 120 ml.
Additionally, a dosing pipette (syringe) is supplied in each pack consisting of a polystyrene plunger and a LDPE-barrel and piston.
Not all pack sizes may be marketed.
Abex Pharmaceutica (Pty) Ltd, Suite C, Rubenstein Ridge, 617 Rubenstein Drive, Moreleta Park, 0181
56/2.6.5/0424
Registration date: 08 August 2023
| Drug | Countries | |
|---|---|---|
| RISPIDE | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.